AMIX

EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing previously reported pain reduction and opioid-free outcomes Late-stage patients showed substantial improvements, suggesting ablation provided clinically meaningful changes even in advanced severe disease THE WOODLANDS, TX, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced results from a post-hoc exploratory subgroup analysis of its previously reported first-in-human proof-of-concept study (PoC 1) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with severe pancreatic cancer pain. The analysis evaluated patient-reported quality-of-life, symptom and functional outcomes as a secondary endpoint of the study using the EORTC QLQ-C30 scale (a validated measure of cancer-specific quality of life) across multiple patient subgroups, including tumor stage and metastatic status. Results from this post-hoc exploratory analysis suggested that Autonomix’s targeted ablation therapy may have produced improvements in symptom burden, functionality, and global quality of life following Autonomix’s targeted ablation therapy. The analysis also provided new procedural findings that will be used to guide Autonomix’s U.S. clinical trial, which is on track to commence in 2026. Key Findings from the Subgroup Analysis: Consistent Improvements Across All Responders: Across all responding patients, average symptom scores improved by 14.53 points at 4–6 weeks (n=9)2 and 26.07 points at 3-months (n=6)2, functionality increased by 8.15 and 25.56 points, and global quality of life improved by 8.33 and 18.06 points, respectively. All 3-month1 results exceeded the EORTC threshold for clinically meaningful change (≥10 points). Advanced Disease in Stage 4, Distant Metastatic Subgroup Shows Strong Response: Patients with Stage 4 pancreatic cancer, with both distant and regional metastases, achieved a 32.48 point symptom improvement and 11.85 point functional gain by 4–6 weeks, maintaining significant benefit at 3-months (29.49 and 25.56 point improvements, respectively). Global quality of life scores improved...

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated Outlines Company’s plans to initiate market expansion study (“POC 2”) into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025 Access the “What This Means” video here THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor “What This Means” segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company’s successfully met initial phase of the first-in-human proof-of-concept trial (“PoC 1”) and the advancement to a follow-on phase (“PoC 2”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain. The “What This Means” video can be accessed here. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram...

THE WOODLANDS, TX, April 24, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced its technology and early proof-of-concept study results will be featured in a poster presentation as part of PCR Innovators Day at the world-leading course in interventional cardiovascular medicine, EuroPCR, being held May 20-23, 2025 in Paris, France. Details of the poster presentation are as follows: Title: Catheter-Based Transvascular RF Neural Ablation For Severe Pancreatic Cancer Pain Elpis StudyPresenting Author: Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc. About EuroPCRSince 1989, PCR has been providing a wide range of practical solutions for independent post-graduate medical education in the constantly evolving field of interventional cardiology. Coronary interventions, valvular disease, hypertension and stroke, peripheral interventions and heart failure are the main themes covered. In all PCR initiatives, better patient care is systematically placed at the core. The flagship PCR Course is EuroPCR, which takes place every month of May in Paris, France. This official meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) is acknowledged as the World-Leading Course in Interventional Cardiovascular Medicine, and gathers 11,000+ participants each year. For more information about EuroPCR 2025 please visit the course website. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address doze...

THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced an abstract detailing its technology and early proof-of-concept study results has been accepted for poster presentation at the 2025 European Conference on Interventional Oncology (ECIO), being held April 13-16, 2025 in Rotterdam, Netherlands. Details of the poster presentation are as follows: Title: Catheter-Based Transvascular RF Neural Ablation for Severe Pancreatic Cancer Pain: First Results from The Elpis Study Authors: Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc, and Askar Uktamovich Sabirov, MD, Primary Investigator, AKFA Medline Hospital About ECIO 2025 The European Conference on Interventional Oncology (ECIO) is renowned as the most comprehensive platform for interventional oncology education and knowledge sharing - bringing together a growing community of experts from around the world for a multidisciplinary program covering all aspects of Interventional Oncology (IO). The conference will feature an outstanding line-up of more than 140 lectures and 16 hands-on training sessions, which will include highlights on topics such as immuno-oncology, revolutions in HCC treatment, pediatric IO, and much more. For more information about the ECIO 2025 please visit the conference website. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hyperten...